Investigation of serum protein profiles in scrapie infected sheep by means of SELDI-TOF-MS and multivariate data analysis

BMC Research Notes

Martha J Ulvund⁴  Anne Hjelle²  Kjetil Bårdsen⁴  Reidar Arneberg³  Olav M Kvalheim¹  Siv Meling⁴ 

[1] Faculty of Health Studies, Sogn og Fjordane University College, N-6800, Førde, Norway;International Research Institute of Stavanger (IRIS, Biomiljø), P.O. Box 8046N-4068, Stavanger, Norway;Department of Innovation, Telemark Technological R&D Centre, Kjølnes ring 30, N-3918, Porsgrunn, Norway;Department of Production Animal Clinical Sciences, Section for Small Ruminant Research, Norwegian School of Veterinary Science, Kyrkjevegen 332-334, N-4325, Sandnes, Norway

关键词: Sheep;    Serum amyloid A;    LC-MS/MS;    Target projection;    PLS-DA;    PCA;    SELDI-TOF-MS;    Scrapie;   

Others  :  1140824
DOI  :  10.1186/1756-0500-6-466

 received in 2013-10-29, accepted in 2013-11-04,  发布年份 2013

【 摘 要 】

Background

Classical scrapie in sheep is a fatal neurodegenerative disease associated with the conversion PrP^C to PrP^Sc. Much is known about genetic susceptibility, uptake and dissemination of PrP^Sc in the body, but many aspects of prion diseases are still unknown. Different proteomic techniques have been used during the last decade to investigate differences in protein profiles between affected animals and healthy controls. We have investigated the protein profiles in serum of sheep with scrapie and healthy controls by SELDI-TOF-MS and LC-MS/MS. Latent Variable methods such as Principal Component Analysis, Partial Least Squares-Discriminant Analysis and Target Projection methods were used to describe the MS data.

Results

The serum proteomic profiles showed variable differences between the groups both throughout the incubation period and at the clinical end stage of scrapie. At the end stage, the target projection model separated the two groups with a sensitivity of 97.8%, and serum amyloid A was identified as one of the protein peaks that differed significantly between the groups.

Conclusions

At the clinical end stage of classical scrapie, ten SELDI peaks significantly discriminated the scrapie group from the healthy controls. During the non-clinical incubation period, individual SELDI peaks were differently expressed between the groups at different time points. Investigations of differences in -omic profiles can contribute to new insights into the underlying disease processes and pathways, and advance our understanding of prion diseases, but comparison and validation across laboratories is difficult and challenging.

【 授权许可】

   
2013 Meling et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

Figure 5.

【 参考文献 】

• [1]EFSA Panel on Biological Hazards (BIOHAZ): Opinion of the Scientific Panel on Biological Hazards on the Breeding programme for TSE resistance in sheep. EFSA J 2006, 382:1-46.
• [2]Ortiz-Pelaez A, Bianchini J: The impact of the genotype on the prevalence of classical scrapie at population level. Vet Res 2011, 42:31. BioMed Central Full Text
• [3]Diaz C, Vitezica ZG, Rupp R, Andreoletti O, Elsen JM: Polygenic variation and transmission factors involved in the resistance/susceptibility to scrapie in a Romanov flock. J Gen Virol 2005, 86:849-857.
• [4]Komolka K, Ponsuksili S, Schwerin M: Healthy sheep that differ in scrapie associated PRNP genotypes exhibit significant differences of expression pattern associated with immune response and cell-to-cell signalling in retropharyngeal lymph nodes. Vet Immunol Immunopathol 2013, 152:370-380.
• [5]Annual reports of Member States on BSE and Scrapie http://ec.europa.eu/food/food/biosafety/tse_bse/monitoring_annual_reports_en.htm webcite
• [6]BSE and other Transmissible Spongiform Encephalopathies (TSEs) http://www.efsa.europa.eu/en/topics/topic/bovinespongiformencephalopathy.htm webcite
• [7]Gill ON, Spencer Y, Richard-Loendt A, Kelly C, Dabaghian R, Boyes L, Linehan J, Simmons M, Webb P, Bellerby P, et al.: Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ 2013, 347:f5675.
• [8]Hunter N, Foster J, Chong A, McCutcheon S, Parnham D, Eaton S, MacKenzie C, Houston F: Transmission of prion diseases by blood transfusion. J Gen Virol 2002, 83:2897-2905.
• [9]Lacroux C, Simon S, Benestad SL, Maillet S, Mathey J, Lugan S, Corbiere F, Cassard H, Costes P, Bergonier D, et al.: Prions in milk from ewes incubating natural scrapie. PLoS Pathog 2008, 4:e1000238.
• [10]Detwiler LA, Baylis M: The epidemiology of scrapie. Rev Sci Tech 2003, 22:121-143.
• [11]Batxelli-Molina I, Salvetat N, Andreoletti O, Guerrier L, Vicat G, Molina F, Mourton-Gilles C: Ovine serum biomarkers of early and late phase scrapie. BMC Vet Res 2010, 6:49. BioMed Central Full Text
• [12]Herbst A, McIlwain S, Schmidt JJ, Aiken JM, Page CD, Li L: Prion disease diagnosis by proteomic profiling. J Proteome Res 2009, 8:1030-1036.
• [13]Huzarewich RL, Siemens CG, Booth SA: Application of “omics” to prion biomarker discovery. J Biomed Biotechnol 2010, 2010:613504.
• [14]Miele G, Seeger H, Marino D, Eberhard R, Heikenwalder M, Stoeck K, Basagni M, Knight R, Green A, Chianini F, et al.: Urinary alpha1-antichymotrypsin: a biomarker of prion infection. PLoS One 2008, 3:e3870.
• [15]Parveen I, Moorby J, Allison G, Jackman R: The use of non-prion biomarkers for the diagnosis of Transmissible Spongiform Encephalopathies in the live animal. Vet Res 2005, 36:665-683.
• [16]Seibert V, Wiesner A, Buschmann T, Meuer J: Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research. Pathol Res Pract 2004, 200:83-94.
• [17]Roche S, Tiers L, Provansal M, Piva MT, Lehmann S: Interest of major serum protein removal for Surface-Enhanced Laser Desorption/Ionization - Time Of Flight (SELDI-TOF) proteomic blood profiling. Proteome Sci 2006, 4:20. BioMed Central Full Text
• [18]Ekblad L, Baldetorp B, Ferno M, Olsson H, Bratt C: In-source decay causes artifacts in SELDI-TOF MS spectra. J Proteome Res 2007, 6:1609-1614.
• [19]Poon TC: Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics 2007, 4:51-65.
• [20]Weinberger SR, Dalmasso EA, Fung ET: Current achievements using ProteinChip Array technology. Curr Opin Chem Biol 2002, 6:86-91.
• [21]Barla A, Jurman G, Riccadonna S, Merler S, Chierici M, Furlanello C: Machine learning methods for predictive proteomics. Brief Bioinform 2008, 9:119-128.
• [22]Sjöström M, Wold S, Söderström B: PLS discriminant plots. In Pattern Recognition in Practice II. Proc., Amsterdam 1985. Edited by Gelsema ES, Kanal LN. Amsterdam; 1986:461-470. xvi, 571 S., $ 79.25; Dfl. 230. ISBN 0444878777
• [23]Rajalahti T, Arneberg R, Berven FS, Myhr KM, Ulvik RJ, Kvalheim OM: Biomarker discovery in mass spectral profiles by means of selectivity ratio plot. Chemometr Intell Lab Syst 2009, 95:35-48.
• [24]Rajalahti T, Arneberg R, Kroksveen AC, Berle M, Myhr KM, Kvalheim OM: Discriminating variable test and selectivity ratio plot: quantitative tools for interpretation and variable (biomarker) selection in complex spectral or chromatographic profiles. Anal Chem 2009, 81:2581-2590.
• [25]Purohit S, Podolsky R, Schatz D, Muir A, Hopkins D, Huang YH, She JX: Assessing the utility of SELDI-TOF and model averaging for serum proteomic biomarker discovery. Proteomics 2006, 6:6405-6415.
• [26]Meling S, Bardsen K, Ulvund MJ: Presence of an acute phase response in sheep with clinical classical scrapie. BMC Vet Res 2012, 8:113. BioMed Central Full Text
• [27]Forshed J, Pernemalm M, Tan CS, Lindberg M, Kanter L, Pawitan Y, Lewensohn R, Stenke L, Lehtio J: Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia. J Proteome Res 2008, 7:2332-2341.
• [28]Whistler T, Rollin D, Vernon SD: A method for improving SELDI-TOF mass spectrometry data quality. Proteome Sci 2007, 5:14. BioMed Central Full Text
• [29]Zhong L, Taylor DL, Whittington RJ: Proteomic profiling of ovine serum by SELDI-TOF MS: optimisation, reproducibility and feasibility of biomarker discovery using routinely collected samples. Comp Immunol Microbiol Infect Dis 2010, 33:47-63.
• [30]Skold M, Ryden T, Samuelsson V, Bratt C, Ekblad L, Olsson H, Baldetorp B: Regression analysis and modelling of data acquisition for SELDI-TOF mass spectrometry. Bioinformatics 2007, 23:1401-1409.
• [31]Eriksson L, Antti H, Gottfries J, Holmes E, Johansson E, Lindgren F, Long I, Lundstedt T, Trygg J, Wold S: Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem 2004, 380:419-429.
• [32]Jackson JE: A User's Guide to Principal Components. New York: John Wiley and Sons, Inc.; 1991.
• [33]Wold S, Sjöström M, Eriksson L: PLS-regression: a basic tool of chemometrics. Chemometr Intell Lab Syst 2001, 58:109-130.
• [34]Kvalheim OM: Interpretation of partial least squares regression models by means of target projection and selectivity plots. J Chemometr 2010, 24:496-504.
• [35]Kvalheim OMKTV: Interpretation of Latent-Variable Regression Models. Chemometr Intell Lab Syst 1989, 7:39-51.
• [36]Bio-Rad: Biomarker Discovery Using SELDI Technology. A Guide to Data Processing and Analysis Using ProteinChip® Data Manager Software. 2008.
• [37]Callesen AK, Mogensen O, Jensen AK, Kruse TA, Martinussen T, Jensen ON, Madsen JS: Reproducibility of mass spectrometry based protein profiles for diagnosis of ovarian cancer across clinical studies: A systematic review. J Proteomics 2012, 75:2758-2772.
• [38]Yip TT, Chan JW, Cho WC, Yip TT, Wang Z, Kwan TL, Law SC, Tsang DN, Chan JK, Lee KC, et al.: Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid a protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clin Chem 2005, 51:47-55.
• [39]Jensen LE, Whitehead AS: Regulation of serum amyloid A protein expression during the acute-phase response. Biochem J 1998, 334(Pt 3):489-503.
• [40]Uhlar CM, Whitehead AS: Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999, 265:501-523.
• [41]Vidal E, Acin C, Foradada L, Monzon M, Marquez M, Monleon E, Pumarola M, Badiola JJ, Bolea R: Immunohistochemical characterisation of classical scrapie neuropathology in sheep. J Comp Pathol 2009, 141:135-146.
• [42]Betmouni S, Perry VH, Gordon JL: Evidence for an early inflammatory response in the central nervous system of mice with scrapie. Neuroscience 1996, 74:1-5.
• [43]Campbell IL, Eddleston M, Kemper P, Oldstone MB, Hobbs MV: Activation of cerebral cytokine gene expression and its correlation with onset of reactive astrocyte and acute-phase response gene expression in scrapie. J Virol 1994, 68:2383-2387.
• [44]Wilcockson DC, Campbell SJ, Anthony DC, Perry VH: The systemic and local acute phase response following acute brain injury. J Cereb Blood Flow Metab 2002, 22:318-326.
• [45]Coe JE, Race RE, Ross MJ: Serological evidence for an inflammatory response in murine scrapie. J Infect Dis 2001, 183:185-191.
• [46]Van GT, Cadron I, Daemen A, De MB, Waelkens E, Vergote I: Proteomic biomarkers predicting lymph node involvement in serum of cervical cancer patients. Limitations of SELDI-TOF MS. Proteome Sci 2012, 10:41. BioMed Central Full Text
• [47]Barr JB, Watson M, Head MW, Ironside JW, Harris N, Hogarth C, Fraser JR, Barron R: Differential protein profiling as a potential multi-marker approach for TSE diagnosis. BMC Infect Dis 2009, 9:188. BioMed Central Full Text
• [48]Diao L, Clarke CH, Coombes KR, Hamilton SR, Roth J, Mao L, Czerniak B, Baggerly KA, Morris JS, Fung ET, et al.: Reproducibility of SELDI Spectra Across Time and Laboratories. Cancer Inform 2011, 10:45-64.
• [49]Dijkstra M, Vonk RJ, Jansen RC: SELDI-TOF mass spectra: a view on sources of variation. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 847:12-23.
• [50]Baggerly KA, Morris JS, Wang J, Gold D, Xiao LC, Coombes KR: A comprehensive approach to the analysis of matrix-assisted laser desorption/ionization-time of flight proteomics spectra from serum samples. Proteomics 2003, 3:1667-1672.
• [51]Ciphergen Biosystems: Ciphergen ProteinChip® Software Version 3.2.1.1216. 2003.
• [52]Bro R, Kjeldahl K, Smilde A, Kiers H: Cross-validation of component models: A critical look at current methods. Anal Bioanal Chem 2008, 390:1241-1251.